etf

Why Biotech ETFs Are Rallying in 2019

From Sanghamitra Saha: This year, biotech stocks have seen their best-ever start to a year since 2012. A solid merger-and-acquisition momentum has been instrumental in this rally. The announcement of the mega-merger deal between Bristol-Myers (BMY – Free Report) and Celgene CELG at the beginning of 2019 has set the space on fire. Bristol-Myers has offered $74 billion to take over Celgene.